• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Reply to "Anti-IL5/IL5R switching between biologics in patients with severe eosinophilic asthma".

作者信息

Eger Katrien, Kroes Johannes A, Ten Brinke Anneke, Bel Elisabeth H

机构信息

Department of Respiratory Medicine, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands.

Department of Clinical Pharmacy and Pharmacology, Medical Center Leeuwarden, Leeuwarden, the Netherlands.

出版信息

J Allergy Clin Immunol Pract. 2022 Jul;10(7):1936. doi: 10.1016/j.jaip.2022.04.018.

DOI:10.1016/j.jaip.2022.04.018
PMID:35809997
Abstract
摘要

相似文献

1
Reply to "Anti-IL5/IL5R switching between biologics in patients with severe eosinophilic asthma".对“重度嗜酸性粒细胞性哮喘患者生物制剂间抗IL5/IL5R转换”的回复
J Allergy Clin Immunol Pract. 2022 Jul;10(7):1936. doi: 10.1016/j.jaip.2022.04.018.
2
Anti-IL5/IL5R switching between biologics in patients with severe eosinophilic asthma.重度嗜酸性粒细胞性哮喘患者在生物制剂之间进行的抗IL5/IL5R转换
J Allergy Clin Immunol Pract. 2022 Jul;10(7):1935-1936. doi: 10.1016/j.jaip.2022.04.017.
3
Features of severe asthma response to anti-IL5/IL5r therapies: identikit of clinical remission.抗 IL-5/IL-5R 治疗重度哮喘反应的特征：临床缓解的特征。
Front Immunol. 2024 Jan 23;15:1343362. doi: 10.3389/fimmu.2024.1343362. eCollection 2024.
4
Increase in FeNO Levels Following IL5/IL5R-Targeting Therapies in Severe Asthma: A Case Series.重度哮喘患者接受IL5/IL5R靶向治疗后呼出气一氧化氮水平升高：病例系列
J Asthma Allergy. 2022 May 19;15:691-701. doi: 10.2147/JAA.S358877. eCollection 2022.
5
Reply to "The immunology of switching biologics in severe eosinophilic asthma patients".对《重度嗜酸性粒细胞性哮喘患者生物制剂转换的免疫学》的回复
J Allergy Clin Immunol Pract. 2021 Sep;9(9):3529. doi: 10.1016/j.jaip.2021.06.029.
6
Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.奥马珠单抗可作为严重哮喘中慢性口服皮质类固醇替代疗法。
Respir Med. 2019 Apr;150:51-62. doi: 10.1016/j.rmed.2019.02.003. Epub 2019 Feb 7.
7
Severe Eosinophilic Allergic Asthma Responsive to Mepolizumab After Failure of 2 Consecutive Biologics.在连续两种生物制剂治疗失败后对美泊利珠单抗有反应的重度嗜酸性粒细胞性过敏性哮喘
J Investig Allergol Clin Immunol. 2019 Feb;29(1):79-81. doi: 10.18176/jiaci.0340.
8
The immunology of switching biologics in severe eosinophilic asthma patients.重度嗜酸性粒细胞性哮喘患者转换生物制剂的免疫学研究
J Allergy Clin Immunol Pract. 2021 Sep;9(9):3528-3529. doi: 10.1016/j.jaip.2021.05.044.
9
Characterization of the interleukin 5-reactive splenic B cell population.
Eur J Immunol. 1990 Sep;20(9):1949-56. doi: 10.1002/eji.1830200912.
10
Severe asthma: what is new in the new millennium.严重哮喘：新千年的新进展。
Curr Opin Allergy Clin Immunol. 2020 Apr;20(2):202-207. doi: 10.1097/ACI.0000000000000623.